3 news items
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
on the ADAS Cog 11." He continued, "Of course, it's preliminary, however together with the SEQUEL where we saw quick response in synaptic health
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
CGTX
15 Mar 24
to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies
CGTX
6 Mar 24
associated with protein trafficking, autophagy, neuroinflammation and microglial response. The third poster summarizes proteomic
- Prev
- 1
- Next